New strategies are needed in diffuse malignant mesothelioma

Kasi S. Sridhar, Xaul Doria, William A. Raub, Richard J. Thurer, Mario Saldana

Research output: Contribution to journalArticle

94 Scopus citations

Abstract

Background. Medical records of 50 patients with malignant mesothelioma were reviewed to determine the clinical features and factors influencing survival. Methods. Charts of all patients whose conditions were diagnosed as malignant mesothelioma were abstracted and analyzed by statistical software. Results. The male-to-female ratio was 4:1. The age distribution was younger than 45 years of age, 10%; 45-54 years of age, 12%; 55-64 years of age, 37%; 65-74 years of age, 33%; and 75 years of age or older, 8%. Both mean and median ages were 58 years. Among the 32 patients in whom asbestos exposure was recorded, 24 had documented exposure. The sites were pleura, 73%; peritoneum, 20%; and both, 6%. The histologic types were epithelial, 51%; sarcomatous, 10%; mixed, 15%; and not specified, 24%. The stage at presentation was Stage I, 37%; II, 39%; III, 12%; IV, 6%; and unknown, 6%. The common symptoms in pleural disease were dyspnea and pain; in peritoneal disease, abdominal distension and pain were common. The median time from first symptom to diagnosis was 3 months (range, 0-23 months). The median survival after the appearance of symptoms, the diagnosis, and the treatment were 13, 10, and 8 months, respectively. Conclusions. The survival was independent of age, sex, and smoking behavior. It was longer in patients with earlier-stage disease, a good performance status, a longer duration of symptoms, an absence of pain, and who were treated with combined surgery and chemotherapy. Chemotherapy using anthracyclines yielded more remissions (9 of 21) than that using nonanthracyclines (0 of 13). The remission rate after primary chemotherapy with anthracyclines (7 of 16) may be higher than in recurrent tumor (2 of 14). In future trials, stratification into primary chemotherapy and chemotherapy of recurrent cancer is suggested. There is a need for multitechnique trials incorporating primary chemotherapy.

Original languageEnglish (US)
Pages (from-to)2969-2979
Number of pages11
JournalCancer
Volume70
Issue number12
DOIs
StatePublished - Dec 15 1992

Keywords

  • doxorubicin
  • mesothelioma
  • metachronous cancers
  • multitechnique therapy
  • pirarubicin
  • primary chemotherapy
  • prochlorperazine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'New strategies are needed in diffuse malignant mesothelioma'. Together they form a unique fingerprint.

  • Cite this

    Sridhar, K. S., Doria, X., Raub, W. A., Thurer, R. J., & Saldana, M. (1992). New strategies are needed in diffuse malignant mesothelioma. Cancer, 70(12), 2969-2979. https://doi.org/10.1002/1097-0142(19921215)70:12<2969::AID-CNCR2820701239>3.0.CO;2-A